This article is part of the supplement: Beyond the Genome: The true gene count, human evolution and disease genomics

Open Badges Invited speaker presentation

Deciphering the genetic basis of common diseases by integrated functional annotation of common and rare variants

Olivier Harismendy12*, Gaurav Bhatia3, Nazli G Rahim4, Vikas Bansal4, Masakazu Nakano4, Michael Scott5, Xiaoyun Wang12, Colette Dib6, Edouard Turlotte6, Nathaniel Heintzman7, Sarah S Murray4, Jean-Francois Deleuze6, Jack C Sipe5, Bing Ren7, Vineet Bafna3, Eric J Topol4 and Kelly A Frazer12

  • * Corresponding author: Olivier Harismendy

Author Affiliations

1 Moores UCSD Cancer Center, USA

2 Department of Pediatrics, University of California Dan Diego, USA

3 Department of Computer Sciences, University of California San Diego, USA

4 Scripps Translational Institute, USA

5 Department of Molecular and Experimental Medicine, The Scripps Research Institute, USA

6 Sanofi-Aventis Evry Genetics Center, USA

7 Ludwig Institute, University of California San Diego, CA 92092, USA

For all author emails, please log on.

Genome Biology 2010, 11(Suppl 1):I8  doi:10.1186/gb-2010-11-s1-i8

The electronic version of this article is the complete one and can be found online at:

Published:11 October 2010

© 2010 Harismendy et al; licensee BioMed Central Ltd.

Invited speaker presentation

Genome-wide associations studies (GWAS) have identified >400 loci associated with common human diseases. Despite the extraordinary achievement that these results represent, several questions remain unanswered: (i) What is the contribution of rare variants to common diseases not addressed by GWAS? (ii) What are the functional variants underlying the GWAS associations?

To answer these questions, we first explored the role of common and rare variants in morbid obesity (BMI>40) by identifying all the variants in the intervals of two endocannabinoid metabolic genes (MGLL and FAAH) using targeted sequencing. We used two different statistical approaches (single marker tests and collapsed markers tests) to identify variants in four intervals associated with high BMI. The majority of the associated variants are located in promoter sequences or in predicted transcriptional enhancers, suggesting their regulatory role. Additionally, we demonstrate that the set of rare variants in the FAAH promoter associated with BMI are also associated with an increased level of anandamide, a FAAH substrate, further suggesting a functional role in obesity. In a second study, we examined one of the most compelling GWAS that had identified SNPs in the 9p21 gene desert associated with coronary artery disease (CAD) and Type 2 diabetes (T2D). We identified 33 enhancers in 9p21; the interval is the second most dense gene-desert for predicted enhancers and is six times denser than the whole genome. The activity of three of these enhancers is affected by regulatory variants that show allelic differences in DNA-protein affinity and are strongly associated with either CAD or T2D. Some of these variants are predicted to disrupt the transcription-binding site relevant to CAD biology. Our study shows that the 9p21 gene desert is significantly enriched in enhancer elements and suggests the associations with CAD and T2D likely result from the cumulative contributions of multiple regulatory variants.

Taken together, our studies show that a comprehensive approach of human genetics that integrates rare variants and functional knowledge, such as regulatory elements or metabolic and cell-specific effects, can leverage the findings of GWAS and lead to a deeper functional understanding of the role of genetic variation in human diseases.